COMMUNIQUÉS West-GlobeNewswire

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
18/07/2025
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene [...]
Generation Bio Announces 1-for-10 Reverse Stock Split
18/07/2025
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced [...]
EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
18/07/2025
Inside Information ALK ( ALKB:DC / OMX: ALK B ) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EUR neffy ® 2 mg in the United Kingdom (UK) for anaphylaxis treatment of [...]
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development
18/07/2025
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development Atif Abbas, MD joins as CMO, bringing over 25 years’ [...]
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
18/07/2025
Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment for people suffering from DPNP THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- Lexicon [...]
Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
18/07/2025
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment [...]
Surgery Partners, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call Details
18/07/2025
BRENTWOOD, Tenn., July 18, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will [...]
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
18/07/2025
CELEBRATION, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Kraig Biocraft Laboratories Nears Strategic Three-Year Government Collaboration to Expand Recombinant Spider Silk Production
18/07/2025
ANN ARBOR, Mich., July 18, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it is finalizing a significant [...]
FOXO TECHNOLOGIES INC. ANNOUNCES INTENTION TO SPIN OFF EPIGENETICS SUBSIDIARY
18/07/2025
WEST PALM BEACH, FLORIDA, July 18, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “ Company ”), today announced that its Board of Directors has approved pursuing the spin-off of its [...]
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
18/07/2025
MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient has [...]
Le KFSHRC réalise la première implantation au monde d’un dispositif BiVAD assisté par robot
18/07/2025
Une chirurgie robotique mini-invasive offre une option vitale aux patients à haut risque qui ne peuvent pas subir de transplantation ou d’intervention à cœur ouvert traditionnelle RIYAD, Arabie saoudite, 18 juill. 2025 [...]
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
18/07/2025
ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal [...]
Orion Group Half-Year Financial Report January–June 2025
18/07/2025
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2025 18 JULY 2025 at 12:00 EEST Orion Group Half-Year Financial Report January–June 2025 April–June 2025 Highlights Net sales totalled EUR 416.5 (April–June 2024: 328.2) [...]
Orion Corporation’s financial reporting and Annual General Meeting in 2026
18/07/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 18 JULY 2025 at 9.30 EEST Orion Corporation’s financial reporting and Annual General Meeting in 2026 Orion Corporation will publish its Financial Statement [...]
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development
18/07/2025
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development Atif Abbas, MD joins as CMO, bringing over 25 years’ [...]
Communiqué de presse : Sanofi finalise l’acquisition de Blueprint Medicines
18/07/2025
Sanofi finalise l’acquisition de Blueprint Medicines Paris, le 18 juillet 2025 . Sanofi annonce aujourd’hui la finalisation de l’acquisition de Blueprint Medicines Corporation (Blueprint). La nouvelle entreprise ajoute [...]
Press Release: Sanofi completes acquisition of Blueprint Medicines
18/07/2025
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025 . Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a [...]
SAPU Bioscience Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients
18/07/2025
Data supports further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma. SAN DIEGO, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Sapu Biosciences [...]

Pages